Floatz logo

Pepinemab

Recurrent Osteosarcoma

Children's Oncology Groupmonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

59 Active assets in the Recurrent Osteosarcoma cohort.

Asset / SponsorPhaseRating
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
(+)-VINCRISTINE
Milton S. Hershey Medical Center
Phase 2BB
Ipilimumab
Children's National Research Institute
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 50 →

Same molecule, other indications

Pepinemab is also rated in:

Huntington diseaseDormant
B
Indicative ·
57 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
Recurrent Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →